Evidence map›Paper›PMID 26239290›Full record

ArticleMolecular psychiatry2015

The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens.

D Y Sakae, F Marti, S Lecca, F Vorspan, E Martín-García, L J Morel, A Henrion, J Gutiérrez-Cuesta, A Besnard, N Heck and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  7. Article
  8. Article
  9. Functional dissociation of behavioral effects from acetylcholine and glutamate released from cholinergic striatal interneurons.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Evolution of regulatory signatures in primate cortical neurons at cell-type resolution.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 4 countries.

D Y SakaeSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
F MartiSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
S LeccaSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
F VorspanFondation FondaMental, Créteil, France.
E Martín-GarcíaDepartament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
L J MorelSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
A HenrionFondation FondaMental, Créteil, France.
J Gutiérrez-CuestaDepartament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
A BesnardSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
N HeckSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
E HerzogSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
S BolteCellular Imaging Facility, Institut de Biologie Paris Seine (IBPS), Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris, France.
V F PradoDepartment of Anatomy and Cell Biology and Department of Physiology and Pharmacology, Robarts Research Institute, The University of Western Ontario, London, ON, Canada.
M A M PradoDepartment of Anatomy and Cell Biology and Department of Physiology and Pharmacology, Robarts Research Institute, The University of Western Ontario, London, ON, Canada.
F BellivierFondation FondaMental, Créteil, France.
C B EapUnit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, Hospital of Cery, Prilly, Switzerland.
S CrettolUnit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, Hospital of Cery, Prilly, Switzerland.
P VanhoutteSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
J CabocheSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
A GrattonDepartment of Psychiatry, Douglas Hospital Research Center, McGill University, Verdun, QC, Canada.
L MoquinDepartment of Psychiatry, Douglas Hospital Research Center, McGill University, Verdun, QC, Canada.
B GirosSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.ORCID http://orcid.org/0000-0001-5876-9822
R MaldonadoDepartament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain.
S DaumasSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
M MameliSorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
S JamainFondation FondaMental, Créteil, France.
S El MestikawySorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France.
Centre National de la Recherche Scientifique · FRInserm · FRUniversitat Pompeu Fabra · ESDélégation Paris 5 · FRDouglas College · CAWestern University · CASorbonne Université · FRUniversity Hospital of Lausanne · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tonically active cholinergic interneurons (TANs) from the nucleus accumbens (NAc) are centrally involved in reward behavior. TANs express a vesicular glutamate transporter referred to as VGLUT3 and thus use both acetylcholine and glutamate as neurotransmitters. The respective roles of each transmitter in the regulation of reward and addiction are still unknown. In this study, we showed that disruption of the gene that encodes VGLUT3 (Slc17a8) markedly increased cocaine self-administration in mice. Concomitantly, the amount of dopamine (DA) release was strongly augmented in the NAc of VGLUT3(-/-) mice because of a lack of signaling by metabotropic glutamate receptors. Furthermore, dendritic spines and glutamatergic synaptic transmission on medium spiny neurons were increased in the NAc of VGLUT3(-/-) mice. Increased DA and glutamate signaling in the NAc are hallmarks of addiction. Our study shows that TANs use glutamate to reduce DA release and decrease reinforcing properties of cocaine in mice. Interestingly, we also observed an increased frequency of rare variations in SLC17A8 in a cohort of severe drug abusers compared with controls. Our findings identify VGLUT3 as an unexpected regulator of drug abuse.

Indexed as

Action PotentialsAdultAnimalsCocaineCocaine-Related DisordersConditioning, OperantDopamineDopamine Uptake InhibitorsGenetic Predisposition to DiseaseGlutamic AcidHumansMiceMice, TransgenicMiddle AgedNeuronsNucleus AccumbensCocaineDopamineDopamine Uptake InhibitorsGlutamic AcidSLC17A8 protein, humanVesicular Glutamate Transport Proteins

Identifiers

PMID26239290
OpenAlexW948220082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.